Collaborative R&D agreement for antibody-drug conjugate (ADC) technology with antibodies to a single oncology targetCollaborative R&d Agreement • May 28th, 2021
Contract Type FiledMay 28th, 2021Abbott Laboratories will pay a $25 million upfront fee to Seattle Genetics for expanded rights to utilize Seattle Genetics' technology for cancer.